Pharmafile Logo
Pharmafocus logo
Advanced Search

Boehringer Ingelheim

Showing 15 posts of 116 posts found.

ipsen_small

Ipsen to acquire Sanofi assets in $88 million deal

February 13, 2017
Sales and Marketing Boehringer Ingelheim, Prontalgine, Sanofi, ipsen

Ipsen has announced that it is set to enter into a definitive agreement to acquire five consumer healthcare products from …

News
bi_german_building_at_night

Boehringer steps into Humira race with US and EU biosimilar filings

January 19, 2017
Sales and Marketing Boehringer Ingelheim, Humira, biosimilar

Boehringer Ingelheim has just stepped into the ring to battle it out for a slice of Humira’s revenue with accepted …

News
handshake

Sanofi and Boehringer confirm successful exchange of businesses

January 3, 2017
Manufacturing and Production, Sales and Marketing Boehringer Ingelheim, Sanofi

Sanofi and Boehringer Ingelheim have confirmed the successful completion of the exchange of Sanofi’s animal health business (Merial, based in …

News
shutterstock_92671375

Five major pharma firms break ABPI code of conduct, according to watchdog

December 15, 2016
Medical Communications, Sales and Marketing ABPI, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Grunenthal, Janssen

Eli Lilly, Boehgringer Ingelheim, AstraZeneca UK, Grunenthal and Janssen-Cilag have been “named and shamed” by the Prescription Medicines Code of …

News

FDA approves another indication for Lilly/Boehringer diabetes treatment

December 5, 2016
Sales and Marketing Boehringer Ingelheim, Eli Lilly, FDA, jardiance

Jardiance (empagliflozin), an oral SGLT02 inhibitor developed by Eli Lilly and distributed by Boehringer Ingelheim, has been approved by the …

News
hanmi

Hanmi Pharmaceutical raided over insider trading suspicions

October 17, 2016
Sales and Marketing Boehringer Ingelheim, Genentech, Hanmi Pharmaceutical, south korea

At the end of September, we reported on a busy 24-hour for Hanmi Pharmaceutical, as they secured a deal with …

News
download

Hanmi Pharma shares crash after shock contract termination

September 30, 2016
Manufacturing and Production, Medical Communications, Research and Development Boehringer Ingelheim, Genentech, Germany, HM61713, Hanmi Pharmaceutical, Tagrisso, south korea

News broke on 29 September that Hanmi Pharma, South Korea’s leading drug maker, had signed a $910 million deal with …

News
cancerstudy

Lilly, Boehringer Ingelheim to jointly study combination therapy for breast cancer

July 14, 2016
Research and Development, Sales and Marketing Boehringer Ingelheim, Eli Lilly, breast cancer, combination therapy, drug trial

US drug major Eli Lilly (NYSE: LLY) and Boehringer Ingelheim said they will jointly initiate early combination trials in breast cancer. The …

News

Boehringer Ingelheim says Phase III trials for its Ofev slowed progression of fatal lung disease

June 27, 2016
Research and Development, Sales and Marketing Boehringer Ingelheim, drug trial, idiopathic pulmonary fibrosis, research

German drugmaker Boehringer Ingelheim said late-stage trials for its Ofev (nintedanib) to treat a fatal lung condition slowed progression of …

News

Sanofi, Boehringer Ingelheim sign definitive agreements for swap

June 27, 2016
Research and Development, Sales and Marketing Boehringer Ingelheim, Financial, Sanofi, business swap, merger and acquisition

French drugmaker Sanofi (Euronext: SAN) and German pharma firm Boehringer Ingelheim have signed a definitive agreement for a business swap announced …

News
simone_menne

Boehringer Ingelheim names Simone Menne new chief financial officer

June 10, 2016
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Boehringer Ingelheim

German drugmaker Boehringer Ingelheim has named Simone Menne as its new chief financial officer. The current CFO at Lufthansa will …

Appointment

FDA approves Lilly/Boehringer Ingelheim type-2 diabetes drug

June 1, 2016
Research and Development, Sales and Marketing Boehringer Ingelheim, Eli Lilly, FDA, diabetes, jentadueto, jentadueto xr, lilly, partnership, type 2, type-2

The US Food and Drug Administration (FDA) has approved Jentadueto XR (linagliptin and metformin hydrochloride extended release) tablets for the …

News

Nice recommends three drugs to treat diabetes

May 25, 2016
Research and Development, Sales and Marketing AstraZeneca, BMS, Boehringer Ingelheim, Eli Lilly, Janssen, NICE, diabetes

The National Institute for Health and Care Excellence (Nice) has backed three drugs for the treatment of type 2 diabetes. …

News
money_pills_2

Horizon to acquire worldwide rights to Boehringer Ingelheim genetic disease drug

May 20, 2016
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Boehringer Ingelheim, actimmune, agreement, horizon, interferon gamma-1b, worldwide rights

Horizon Pharmaceuticals (NASDAQ: HZNP) has entered into a worldwide rights agreement with Boehringer Ingelheim to acquire interferon gamma-1b, which is …

News
bi_german_building_at_night

Boehringer Ingelheim says new studies underline efficacy of lung disease drug

May 18, 2016
Research and Development, Sales and Marketing Boehringer Ingelheim, lung disease

Boehringer Ingelheim said late-stage trials for its drug to treat chronic lung disease reinstate its efficacy and safety profile. The …

News
The Gateway to Local Adoption Series

Latest content

Rhythm AI’s STAR Apollo system receives FDA clearance for atrial fibrillation

February 12, 2026

iOrganBio appoints Karol Jarzabek as Chief Operating Officer

February 12, 2026

Ensera Design expands UK leadership team with new senior appointments

February 11, 2026

Infinitopes announces $15.4m in additional seed funding to advance cancer vaccine

February 11, 2026

Angelini Pharma appoints Roberto Scrivo as Chief of External Affairs, Communication and Sustainability Officer

February 10, 2026